198 related articles for article (PubMed ID: 1355853)
21. Comparison of cladribine plus cyclophosphamide with fludarabine plus cyclophosphamide as first-line therapy for chronic lymphocytic leukemia: a phase III randomized study by the Polish Adult Leukemia Group (PALG-CLL3 Study).
Robak T; Jamroziak K; Gora-Tybor J; Stella-Holowiecka B; Konopka L; Ceglarek B; Warzocha K; Seferynska I; Piszcz J; Calbecka M; Kostyra A; Dwilewicz-Trojaczek J; Dmoszyñska A; Zawilska K; Hellmann A; Zdunczyk A; Potoczek S; Piotrowska M; Lewandowski K; Blonski JZ
J Clin Oncol; 2010 Apr; 28(11):1863-9. PubMed ID: 20212251
[TBL] [Abstract][Full Text] [Related]
22. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
Kay AC; Saven A; Carrera CJ; Carson DA; Thurston D; Beutler E; Piro LD
J Clin Oncol; 1992 Mar; 10(3):371-7. PubMed ID: 1346801
[TBL] [Abstract][Full Text] [Related]
23. 2-Chlorodeoxyadenosine (2-CdA) in the treatment of patients with relapsed chronic lymphocytic leukemia.
Krykowski E; Warzocha K; Robak T
Arch Immunol Ther Exp (Warsz); 1995; 43(5-6):317-21. PubMed ID: 8744653
[TBL] [Abstract][Full Text] [Related]
24. Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma.
Zinzani PL; Levrero MG; Lauria F; Rondelli D; Zaja F; Russo D; Fanin R; De Rossi G; Mauro FR; Bendandi M; Gozzetti A; Dianzani F; Mandelli F; Tura S
Haematologica; 1994; 79(1):55-60. PubMed ID: 15378949
[TBL] [Abstract][Full Text] [Related]
25. Fludarabine and prednisone in pretreated and refractory B-chronic lymphocytic leukemia (B-CLL) in advanced stages.
De Rossi G; Mauro FR; Caruso R; Monarca B; Mandelli F
Haematologica; 1993; 78(3):167-71. PubMed ID: 8375746
[TBL] [Abstract][Full Text] [Related]
26. [Fludarabine treatment of chronic lymphoid leukemia].
Gabeeva NG; Pivnik AV; Moiseeva TN; Zybunova EE; Samoĭlova RS; Kremenetskaia AM; Varlamova EIu; Kaplanskaia IB
Ter Arkh; 2000; 72(8):42-5. PubMed ID: 11019427
[TBL] [Abstract][Full Text] [Related]
27. Fludarabine, ara-C, novantrone and dexamethasone (FAND) in previously treated chronic lymphocytic leukemia patients.
Mauro FR; Foa R; Meloni G; Gentile M; Giammartini E; Giannarelli D; De Propris MS; Rapanotti MC; de Fabritiis P; Mandelli F
Haematologica; 2002 Sep; 87(9):926-33. PubMed ID: 12217804
[TBL] [Abstract][Full Text] [Related]
28. [Treatment with fludarabine of lymphoid neoplasms with low grade malignity resistant to treatment or in relapse].
Briones J; Montserrat E; Urbano-Ispizua A; Esteve J; Colomer D; López-Guillermo A; Bosch F; Hadjieu E; Rozman C
Med Clin (Barc); 1996 Jun; 107(3):86-9. PubMed ID: 8754493
[TBL] [Abstract][Full Text] [Related]
29. High-dose methylprednisolone can induce remissions in patients with fludarabine-refractory chronic lymphocytic leukaemia.
Xu W; Miao KR; Hong M; Zhu DX; Fang C; Dong HJ; Wang DM; Cao X; Li JY
Eur J Cancer; 2010 Aug; 46(12):2145-9. PubMed ID: 20627536
[TBL] [Abstract][Full Text] [Related]
30. Treatment of refractory T-cell chronic lymphocytic leukemia with purine nucleoside analogues.
Witzig TE; Weitz JJ; Lundberg JH; Tefferi A
Leuk Lymphoma; 1994 Jun; 14(1-2):137-9. PubMed ID: 7920220
[TBL] [Abstract][Full Text] [Related]
31. [Treatment of chronic lymphatic leukemia].
Adam Z; Vorlícek J; Hejlová N
Vnitr Lek; 1996 Aug; 42(8):573-8. PubMed ID: 8967031
[TBL] [Abstract][Full Text] [Related]
32. Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Tsimberidou AM; Kantarjian HM; Cortes J; Thomas DA; Faderl S; Garcia-Manero G; Verstovsek S; Ferrajoli A; Wierda W; Alvarado Y; O'Brien SM; Albitar M; Keating MJ; Giles FJ
Cancer; 2003 Apr; 97(7):1711-20. PubMed ID: 12655528
[TBL] [Abstract][Full Text] [Related]
33. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia.
O'Brien S; Moore JO; Boyd TE; Larratt LM; Skotnicki A; Koziner B; Chanan-Khan AA; Seymour JF; Bociek RG; Pavletic S; Rai KR
J Clin Oncol; 2007 Mar; 25(9):1114-20. PubMed ID: 17296974
[TBL] [Abstract][Full Text] [Related]
34. Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells.
Bouzar AB; Boxus M; Defoiche J; Berchem G; Macallan D; Pettengell R; Willis F; Burny A; Lagneaux L; Bron D; Chatelain B; Chatelain C; Willems L
Br J Haematol; 2009 Jan; 144(1):41-52. PubMed ID: 19006566
[TBL] [Abstract][Full Text] [Related]
35. Purine analogs in the treatment of chronic lymphocytic leukemia.
Pott C; Hiddemann W
Leukemia; 1997 Apr; 11 Suppl 2():S25-8. PubMed ID: 9178834
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia.
Rossi JF; van Hoof A; de Boeck K; Johnson SA; Bron D; Foussard C; Lister TA; Berthou C; Kramer MH; Littlewood TJ; Marcus RE; Deconinck E; Montillo M; Guibon O; Tollerfield SM
J Clin Oncol; 2004 Apr; 22(7):1260-7. PubMed ID: 15051774
[TBL] [Abstract][Full Text] [Related]
37. Present status of purine analogs in the therapy of chronic lymphocytic leukemias.
Bergmann L
Leukemia; 1997 Apr; 11 Suppl 2():S29-34. PubMed ID: 9178835
[TBL] [Abstract][Full Text] [Related]
38. Alkylating agents and nucleoside analogues in the treatment of B cell chronic lymphocytic leukemia.
Robak T; Kasznicki M
Leukemia; 2002 Jun; 16(6):1015-27. PubMed ID: 12040433
[TBL] [Abstract][Full Text] [Related]
39. 2-Chlorodeoxyadenosine produces a high rate of complete hematologic remission in relapsed acute myeloid leukemia.
Santana VM; Mirro J; Kearns C; Schell MJ; Crom W; Blakley RL
J Clin Oncol; 1992 Mar; 10(3):364-70. PubMed ID: 1346800
[TBL] [Abstract][Full Text] [Related]
40. Retreatment of chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission: no acquired resistance.
Juliusson G; Liliemark J
Leuk Lymphoma; 1994 Mar; 13(1-2):75-80. PubMed ID: 8025525
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
